|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chiarini F, Evangelisti C, McCubrey JA and
Martelli AM: Current treatment strategies for inhibiting mTOR in
cancer. Trends Pharmacol Sci. 36:124–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Iwaya T, Yokobori T, Nishida N, Kogo R,
Sudo T, Tanaka F, Shibata K, Sawada G, Takahashi Y, Ishibashi M, et
al: Downregulation of miR-144 is associated with colorectal cancer
progression via activation of mTOR signaling pathway.
Carcinogenesis. 33:2391–2397. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee DF, Kuo HP, Chen CT, Hsu JM, Chou CK,
Wei Y, Sun HL, Li LY, Ping B, Huang WC, et al: IKK beta suppression
of TSC1 links inflammation and tumor angiogenesis via the mTOR
pathway. Cell. 130:440–455. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sarbassov DD, Ali SM, Kim DH, Guertin DA,
Latek RR, Erdjument-Bromage H, Tempst P and Sabatini DM: Rictor, a
novel binding partner of mTOR, defines a rapamycin-insensitive and
raptor-independent pathway that regulates the cytoskeleton. Curr
Biol. 14:1296–1302. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jacinto E, Loewith R, Schmidt A, Lin S,
Rüegg MA, Hall A and Hall MN: Mammalian TOR complex 2 controls the
actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol.
6:1122–1128. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sarbassov DD, Guertin DA, Ali SM and
Sabatini DM: Phosphorylation and regulation of Akt/PKB by the
rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jacinto E, Facchinetti V, Liu D, Soto N,
Wei S, Jung SY, Huang Q, Qin J and Su B: SIN1/MIP1 maintains
rictor-mTOR complex integrity and regulates Akt phosphorylation and
substrate specificity. Cell. 127:125–137. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pearce LR, Huang X, Boudeau J, Pawłowski
R, Wullschleger S, Deak M, Ibrahim AF, Gourlay R, Magnuson MA and
Alessi DR: Identification of Protor as a novel Rictor-binding
component of mTOR complex-2. Biochem J. 405:513–522. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tsuruta T, Kozaki K, Uesugi A, Furuta M,
Hirasawa A, Imoto I, Susumu N, Aoki D and Inazawa J: miR-152 is a
tumor suppressor microRNA that is silenced by DNA hypermethylation
in endometrial cancer. Cancer Res. 71:6450–6462. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
McDonald PC, Oloumi A, Mills J, Dobreva I,
Maidan M, Gray V, Wederell ED, Bally MB, Foster LJ and Dedhar S:
Rictor and integrin-linked kinase interact and regulate Akt
phosphorylation and cancer cell survival. Cancer Res. 68:1618–1624.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Agarwal NK, Chen CH, Cho H, Boulbès DR,
Spooner E and Sarbassov DD: Rictor regulates cell migration by
suppressing RhoGDI2. Oncogene. 32:2521–2526. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Serrano I, McDonald PC, Lock FE and Dedhar
S: Role of the integrin-linked kinase (ILK)/Rictor complex in
TGFβ-1-induced epithelial-mesenchymal transition (EMT). Oncogene.
32:50–60. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Verreault M, Weppler SA, Stegeman A,
Warburton C, Strutt D, Masin D and Bally MB: Combined RNAi-mediated
suppression of Rictor and EGFR resulted in complete tumor
regression in an orthotopic glioblastoma tumor model. PLoS One.
8:e595972013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Oneyama C, Kito Y, Asai R, Ikeda J,
Yoshida T, Okuzaki D, Kokuda R, Kakumoto K, Takayama K, Inoue S, et
al: miR-424/503-mediated Rictor upregulation promotes tumor
progression. PLoS One. 8:e803002013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang F, Zhang X, Li M, Chen P, Zhang B,
Guo H, Cao W, Wei X, Cao X, Hao X and Zhang N: mTOR complex
component Rictor interacts with PKCzeta and regulates cancer cell
metastasis. Cancer Res. 70:9360–9370. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen CH, Shaikenov T, Peterson TR,
Aimbetov R, Bissenbaev AK, Lee SW, Wu J, Lin HK and dos Sarbassov
D: ER stress inhibits mTORC2 and Akt signaling through
GSK-3β-mediated phosphorylation of rictor. Sci Signal. 4:ra102011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bashir T, Cloninger C, Artinian N,
Anderson L, Bernath A, Holmes B, Benavides-Serrato A, Sabha N,
Nishimura RN, Guha A and Gera J: Conditional astroglial Rictor
overexpression induces malignant glioma in mice. PLoS One.
7:e477412012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Feldman ME, Apsel B, Uotila A, Loewith R,
Knight ZA, Ruggero D and Shokat KM: Active-site inhibitors of mTOR
target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol.
7:e382009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yu K, Toral-Barza L, Shi C, Zhang WG,
Lucas J, Shor B, Kim J, Verheijen J, Curran K, Malwitz DJ, et al:
Biochemical, cellular, and in vivo activity of novel
ATP-competitive and selective inhibitors of the mammalian target of
rapamycin. Cancer Res. 69:6232–6240. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Thoreen CC, Kang SA, Chang JW, Liu Q,
Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM and Gray NS: An
ATP-competitive mammalian target of rapamycin inhibitor reveals
rapamycin-resistant functions of mTORC1. J Biol Chem.
284:8023–8032. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Roulin D, Cerantola Y, Dormond-Meuwly A,
Demartines N and Dormond O: Targeting mTORC2 inhibits colon cancer
cell proliferation in vitro and tumor formation in vivo. Mol
Cancer. 9:572010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Faivre S, Kroemer G and Raymond E: Current
development of mTOR inhibitors as anticancer agents. Nat Rev Drug
Discov. 5:671–688. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guertin DA and Sabatini DM: Defining the
role of mTOR in cancer. Cancer Cell. 12:9–22. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gulhati P, Cai Q, Li J, Liu J, Rychahou
PG, Qiu S, Lee EY, Silva SR, Bowen KA, Gao T and Evers BM: Targeted
inhibition of mammalian target of rapamycin signaling inhibits
tumorigenesis of colorectal cancer. Clin Cancer Res. 15:7207–7216.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Im-aram A, Farrand L, Bae SM, Song G, Song
YS, Han JY and Tsang BK: The mTORC2 component rictor contributes to
cisplatin resistance in human ovarian cancer cells. PLoS One.
8:e754552013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hietakangas V and Cohen SM: TOR complex 2
is needed for cell cycle progression and anchorage-independent
growth of MCF7 and PC3 tumor cells. BMC Cancer. 8:2822008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kuo PL, Hsu YL and Cho CY: Plumbagin
induces G2-M arrest and autophagy by inhibiting the AKT/mammalian
target of rapamycin pathway in breast cancer cells. Mol Cancer
Ther. 5:3209–3221. 2006. View Article : Google Scholar : PubMed/NCBI
|
